Who is sponsoring NCT04266600?

NCT04266600 is sponsored by Jewish General Hospital.

What drugs are being tested in NCT04266600?

Interventions in NCT04266600: Extensive mesentery resection.

What condition does NCT04266600 study?

NCT04266600 studies Crohn Disease, Recurrence, Crohn's Ileocolitis.

Is NCT04266600 still recruiting?

NCT04266600 is currently status unknown. Last updated 19 May 2021.

Last reviewed 2021-05-19 · How we verify

NCT04266600

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease

Status unknown NA Last updated 19 May 2021

What this trial tests

NA trial testing Extensive mesentery resection in Crohn Disease in 29 participants. Status unknown.

Timeline

27 September 2019

Primary endpoint
27 September 2023

27 September 2024

Quick facts

Lead sponsor	Jewish General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	29
Start date	27 September 2019
Primary completion	27 September 2023
Estimated completion	27 September 2024
Sites	2 locations across Canada

Drugs / interventions tested

Extensive mesentery resection

Conditions studied

Crohn Disease — all drugs for Crohn Disease →
Recurrence — all drugs for Recurrence →
Crohn's Ileocolitis — all drugs for Crohn's Ileocolitis →

Sponsor

Jewish General Hospital

Who can join

18 and older, any sex, with Crohn Disease or Recurrence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is looking at the role of the mesentery in disease recurrence for ileocolic Crohn's disease. It is a prospective study that has been designed to perform extended mesenteric excision on patients undergoing their first ileocolic resection for Crohn's disease. Endoscopic recurrence will be monitored with the hypothesis that patients receiving extended mesenteric ileocolic resection will have reduced endoscopic recurrence at 6 months after resection. (limited mesenteric resection).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Extended versus limited mesenteric excision in bowel resection for Crohn's disease: a meta-analysis and systematic review.
Pompeu BF, Marcolin P, Marques FILCB, da Rocha Soares GA, et al · · 2025 · cited 6× · PMID 40057916 · DOI 10.1007/s10151-024-03108-w
Intriguing Role of the Mesentery in Ileocolic Crohn's Disease.
Turri G, Carvello M, Ben David N, Spinelli A. · · 2022 · cited 3× · PMID 35966976 · DOI 10.1055/s-0042-1743590
Effect of extensive mesenteric excision on primary ileocolic resection outcomes in Crohn's disease patients: a systematic review with meta-analysis.
Martínez-Pérez A, Schena CA, Pellino G, Martínez-López E, et al · · 2025 · PMID 41329358 · DOI 10.1007/s00384-025-05043-0

Verify or expand the search:

Other recruiting trials for Crohn Disease

Currently open trials in the same condition.

NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07310095 — A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) · Phase 4 · recruiting
NCT07364734 — Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease · recruiting
NCT07170462 — Cranberry and Gut Health in Crohn's Disease · EARLY_PHASE1 · recruiting
NCT07196722 — A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease · Phase 2, PHASE3 · recruiting

Other Jewish General Hospital trials

Trials by the same sponsor.

NCT05188222 — Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery · Phase 4 · not yet recruiting
NCT06701929 — The Impact of Fasting Duration on Quality of Recovery After Cesarean Section · recruiting
NCT05719415 — Functional Pulmonary Capillary Surface Area in BPA for CTEPH · NA · recruiting
NCT04678986 — ER2 and Deep Learning for Prediction of Adverse Health Outcomes · withdrawn
NCT04893876 — The OPERa Study: Evaluating QoL After Rectal Cancer Surgery · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04266600 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jewish General Hospital
Last refreshed: 19 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04266600.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing